How to Help Your Patients Find Lagevrio in Stock: A Provider's Guide

When you prescribe Lagevrio (molnupiravir) to a COVID-positive patient, the clock starts immediately. The medication must be initiated within five days of symptom onset. In 2026, commercial pharmacy stocking of Lagevrio is inconsistent — meaning patients often face a scramble to find it when they need it most. This guide gives your care team concrete tools and a workflow to maximize the likelihood your patients successfully access their treatment.

Why Lagevrio Is Harder to Find Than Paxlovid

Lagevrio occupies a second-line position in COVID treatment guidelines — prescribed when Paxlovid is contraindicated or inaccessible. This means lower prescription volume, which drives lower pharmacy stocking. At $1,100+ per course retail, pharmacies are reluctant to stock units that may expire. And since government distribution ended and all HHS stock expired by February 2025, there are no federally subsidized access pathways remaining for most patients.

Tool 1: medfinder for Providers

The most efficient tool for locating Lagevrio availability is medfinder for Providers. medfinder contacts pharmacies near your patient's location to check which ones have Lagevrio in stock. Your care team can use this to verify availability before routing the prescription, eliminating back-and-forth delays.

This is especially valuable during seasonal COVID surges when stocking is most unpredictable.

Tool 2: MerckHelps Patient Assistance Program

For uninsured patients who cannot afford Lagevrio, the MerckHelps program (merckhelps.com/lagevrio, 1-800-727-5400) can provide the medication at no cost. Providers or their designees can initiate expedited requests by calling directly — and if approved, Lagevrio can be shipped overnight to the patient's home address. This is an underused option that can be life-changing for eligible patients in urgent situations.

Patient eligibility criteria: primarily uninsured patients who cannot otherwise afford the medication. Patients with insurance but facing financial hardship may also qualify under certain circumstances. Enroll patients at the point of prescribing, not afterward.

Tool 3: Merck Savings Coupon for Insured Patients

Patients with private insurance may be eligible for a savings coupon through Merck's website (lagevrio.com/patients/coupon) that reduces their out-of-pocket cost. Direct patients and caregivers to this resource when prescribing. Even with insurance, high-deductible plans can make Lagevrio prohibitively expensive without the coupon.

Pharmacy Strategy: Where to Send the Prescription

Based on real-world stocking patterns, the following pharmacy types are more likely to carry Lagevrio:

Hospital outpatient pharmacies: Often maintain broader antiviral formularies. Worth routing prescriptions here for high-risk patients.

Independent community pharmacies: May stock Lagevrio specifically because of their patient population's needs. Often more responsive to special orders.

HRSA-supported health centers: Federal entities including HRSA health centers retained access to federal antiviral stock. Eligible patients receiving care at these facilities may have better access.

Recommended Provider Workflow

Confirm Lagevrio availability before sending the prescription — use medfinder for Providers or call hospital pharmacies in your area

Route prescription directly to a confirmed pharmacy — don't leave it to the patient to figure out

Enroll uninsured patients in MerckHelps at time of prescribing — this can be done while the patient is still in your office or on the phone

Provide EUA Fact Sheet and document receipt — required under EUA terms

Have contingency plan ready — if Lagevrio cannot be located, have Remdesivir infusion center referral ready before the 5-day window closes

Patient Education Points at Prescribing

They must start Lagevrio within 5 days of symptom onset — acting quickly is critical

Do not stop after 4 days even if feeling better — complete the full 5-day course

Swallow capsules whole — do not open, break, or crush

Continue COVID isolation precautions during treatment per current CDC guidance

For a broader clinical overview, see our Lagevrio shortage briefing for providers.